Logo-ipp

Immunopathol Persa. 2023;9(2): 29293. doi: 10.34172/ipp.2022.29293

Original

Cost-effectiveness analysis of infliximab versus CinnoRA in the treatment of moderate to severe ulcerative colitis in Iranian patients

Meysam Olfatifar 1 ORCID, Hamid Asadzadeh Aghdaei 2 * ORCID, Ayda Hasanpour Dehkordi 3 ORCID, Shabnam Shahrokh 1, Mohamad Amin Pourhoseingholi 1 ORCID, Hedieh Balaii 2 ORCID, Mohsen Rajabnia 1 ORCID, Maria Ivanchuk 4 ORCID, Pavlo Ivanchuk 5 ORCID, Saeed Hashemi Nazari 6 * ORCID, Siamak Sabour 7,8 ORCID, Pejman Rohani 9 ORCID, Gholamhossein Mehralian 10 ORCID, Soheila Khodakarim 11 ORCID, Behzad Hatami 1 ORCID, Habib Malekpour 2, Ghazal Sherkat 12 ORCID, Mohammad Reza Zali 1 * ORCID, Sajjad Rahimi Pordanjani 13,14 ORCID

Cited by CrossRef: 1

1- Bas T, Duarte V. Biosimilars in the Era of Artificial Intelligence—International Regulations and the Use in Oncological Treatments. Pharmaceuticals. 2024;17(7):925 [Crossref]